CRSP vs NTLA
CRSP: CRISPR Therapeutics is a biopharmaceutical company pioneering gene-editing therapies to treat and potentially cure severe genetic diseases using its proprietary CRISPR/Cas9 technology. NTLA: Intellia Therapeutics is a genome editing pioneer developing CRISPR/Cas9-based, potentially curative in vivo therapies for genetic diseases.
Side-by-side fundamentals
| Metric | CRSP | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $49.88 | $11.84 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-20) | $4.8B | $1.7B | |
| Net margin FY2025, SEC XBRL | -16569.8% | -609.9% | NTLA higher |
| Operating margin FY2025, SEC XBRL | -18933.6% | -651.7% | NTLA higher |
| ROE FY2025, SEC XBRL | -30.3% | -61.5% | CRSP higher |
| ROA FY2025, SEC XBRL | -25.7% | -49.0% | CRSP higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.34 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | -90.6% | +16.9% | NTLA higher |
| Revenue CAGR (3y) SEC XBRL | +43.1% | +9.1% | CRSP higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.43 | 1.66 | |
| 1-year return as of 2026-10-20 close | -32.6% | -57.7% | CRSP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.